Background: Thirteen studies investigating the association between asthma during pregnancy and perinatal mortality reported generally no increased risk. Most of these studies should be interpreted with caution because they were limited in terms of statistical power.
INTRODUCTION
Asthma is considered the most prevalent medical condition to complicate pregnancy. (1) Around 4% to 8% of pregnancies are complicated by asthma. (1) Studies that have evaluated the effect of maternal asthma on perinatal mortality suggest that it does not significantly increase the risk (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , except one (13) . Indeed, Gordon et al., (13) reported a statistically significant increased risk of perinatal mortality among 273 asthmatic women (5.9%) compared to 30 861 non-asthmatic women (3.2%) (p<0.05). It is worth noting, however, that the conclusion of this study was based on crude estimates. The risk of stillbirth (2;8;14-20) and neonatal mortality (2;8;14-17;20) associated with maternal asthma have been evaluated in several studies but no statistically significant increased risk was reported, except in the study realised by Bahna et al. (2) Moreover, most of the negative studies should be interpreted with caution due to small sample size and lack of power (3) (4) (5) (6) (7) (8) (9) (10) (11) that limits the capacity of the studies to conclude to the absence of an association with a reasonable degree of certainty. Among the negative study, Tata et al. (21) were the only authors who performed a study with a power >80% to detect the observed relative risk.
In order to better quantify the association between maternal asthma and perinatal mortality, we conducted a large cohort study formed of 41 142 pregnancies from asthmatic and non-asthmatic women using the health administrative databases of the Canadian province of Québec.
METHODS

Source of data
Our cohort of pregnancies was constructed through the linkage of three health administrative databases from Québec, Canada. The administrative database of the Régie de l'assurancemaladie du Québec (RAMQ) provides information related to the medical services dispensed to all residents of Québec as well as information related to medication prescriptions filled at community pharmacies for those residents who are covered by the Quebec's Public Prescription Drug Insurance Plan, which represents approximately 43 % of the population. The MED-ECHO database contains information on all hospital admissions in Québec. Administered by the Institut de la statistique du Québec (ISQ), the Fichier des événements démographiques provides information on all births and perinatal deaths.
Study population
We constructed a cohort formed of singleton pregnancies of all asthmatic women and a 33 % random sample of non-asthmatic women, who had at least one delivery -live birth or stillbirthbetween 1990 and 2002, were covered by the Quebec's Public Prescription Drug Insurance Plan for at least one year before conception and during pregnancy, and aged between 13 and 50 years at conception. Pregnancies were identified using diagnostic and act codes related to prenatal care, pregnancy complications, and delivery care. The calendar date of the conception, first day of last menstrual period, was retrospectively calculated by subtracting the gestational age from the offspring's date of birth as recorded in the MED-ECHO and RAMQ databases. These databases have been used in the past for epidemiological research in the field of asthma. (22) The main exposure was maternal asthma. A woman was considered as an asthmatic if she filled had at least one prescription for an asthma medication and had at least one diagnosis of asthma in accordance with the International Classification of Diseases, 9 th revision, (ICD-9) -codes 493.0, 493.1, 493.9 -either two years before or during her pregnancy. Once a woman was identified as having asthma, her status was kept unchanged for all subsequent pregnancies. The medical diagnosis for asthma recorded in the RAMQ Medical Services database have been formally evaluated and found to be valid. (23) A women was considered as non-asthmatic if she filled no prescription for an asthma medication between 1988 and 2002 and had no diagnosis for asthma during the entire follow-up.
Definition of Outcomes
Perinatal mortality included stillbirth and neonatal mortality. Stillbirth was defined as foetal loss beyond 20 weeks of gestation or if the gestational age is unknown, a birth weight of 500 g or more, which corresponds to 22 weeks of gestation in a normally developing foetus. Stillbirths were identified with ICD-9 codes 656.4, V27.1, V27.3, V27.4, V27.6, V27.7, V32, V35, V36 recorded in the RAMQ, MED-ECHO or birth and death certificate databases. Neonatal mortality was defined as the death of a liveborn neonate within the first 29 days of life. Deaths occurring within the first 29 days of life were identified from the ISQ or RAMQ database.
Potential confounding variables
Three categories of variables, identified in the literature, including maternal characteristics, pregnancy related variables and foetal characteristics were considered as potential confounders. Maternal characteristics included the age at conception (< 18 years old, 18-34 years old, ≥ 35 years old), receiving benefits from Quebec's Social Assistance Program during the pregnancy (yes/no), and the level of education during the pregnancy (≤ 11 years ≥ 12 years, missing values). The pregnancy related variables included parity (first /second or more pregnancy), pregnancy induced hypertension (PIH) (yes/no), diabetes mellitus (yes/no), gestational diabetes (yes/no), placental abruption (yes/no) and infection of amniotic cavity (yes/no). Using specific algorithms that we developed for each condition, PIH, gestational diabetes and diabetes mellitus were identified based upon either a diagnosis or a filled prescription for a related medication as recorded in the RAMQ or MED-ECHO databases one year before or during the pregnancy. These variables were defined previously (24) and the algorithms are available upon request. Foetal characteristics included cord around the neck (yes/no) based on a diagnosis recorded in the RAMQ or MED-ECHO databases, as well as birth weight (≤2500g/>2500g), gestational age at birth (<37 weeks/ ≥ 37 weeks) and small for gestational age (SGA) (yes/no). Algorithms to measure birth weight and gestational age at birth from the data available in the MED-ECHO and ISQ databases have been developed and found to be highly valid when compared to data recorded in the mother's medical chart. (25)
Statistical analysis
To compare the risk of perinatal mortality between asthmatic and non-asthmatic women we used Generalized Estimation Equations (GEE) models with a logistic link and we included potential confounders in these models. GEE models were used to estimate the correlation between pregnancies from the same women and to provide valid variance estimates. Seven models were used: 1) a crude model including only the maternal asthma variable (main exposure); 2) a full and a reduced model including the maternal asthma variable and considering all potential confounding variables except SGA; 3) a full and a reduced model including the maternal asthma variable and considering all potential confounding variables except birth weight, gestational age at birth and SGA; 4) a full and a reduced model including the maternal asthma variable and considering all potential confounding variables except birth weight and gestational age.
Since maternal asthma has been found to increase the risk of having a low birth weight baby (2;5;17) and premature delivery, (2;17;26) and that both perinatal death (27;28) we performed a stratified analysis to further investigate the role of these variables in the causal pathway between maternal asthma and perinatal mortality. The association between maternal asthma and perinatal mortality was thus studied among women who had a baby with a birth weight ≤ 2500 g or born before the 37 th week of gestation and among women who had a baby with a birth weight > 2500 g and born at 37 weeks of gestation or more, separately. These analyses were adjusted for all potential confounding variables listed above, except SGA.
We used a backward selection strategy to select the set of confounders. This strategy consists in eliminating one by one the variables that does not act as a confounder in the model, starting with all potential confounding variables in the model. When we excluded a variable from the model and the odds ratio of asthma changed by more than 10%, we considered that as confounder, and it was re introduced in the model. The final model was found when no variable can be removed from the model without modifying the odds ratio of maternal asthma by 10% or more. Analyses were performed with SAS version 9.
RESULTS
The cohort was formed of 41 142 singleton pregnancies; 13 100 born to asthmatic women and 28 042 in non-asthmatic women. The rate of stillbirth and perinatal mortality among asthmatic women were respectively 0.56 % and 1.04 %. The corresponding rates for non-asthmatic women were 0.47% and 0.77%.
In Table 1 , we present the characteristics of asthmatic and non-asthmatic pregnant women included in the cohort. The unit of analysis is the pregnancy since 23 % of the women contributed more than one pregnancy in the analysis. Asthmatic women were more likely to have a low birth weight baby and a preterm delivery than non-asthmatic women. Table 1 also shows the prevalence of perinatal mortality as a function of each covariable: women who had a placental abruption, an infection of the amniotic cavity, a low birth weight baby and a premature delivery had a greater risk of perinatal mortality. Table 2 presents the results of the GEE models that were used to investigate the risk of perinatal mortality between asthmatic and non-asthmatic women including all potential confounding variables, except SGA. A statistically significant crude increased risk of perinatal mortality was observed among asthmatic women compared to non-asthmatic women (OR= 1.35 (95% CI: 1.08-1.67)). After adjusting for all potential confounders, the OR decreased to 0.93; (95% CI: 0.75-1.17). The reduced model revealed that only birth weight and gestational age at birth acted as confounders in the asthma/perinatal mortality association. It is also worth noting that low birth weight and preterm birth were found to be very strong crude predictors of perinatal mortality with significant OR of 34.8 and 30.6, but that these OR reduced to 9.11 and 7.07, respectively, after adjusting for maternal asthma. On the other hand, the full and the reduce models excluding birth weight, gestational age at birth and SGA showed that asthmatic women tended to be more at risk of perinatal mortality than non-asthmatic women (adjusted OR=1.25; 95% CI: 0.98-1.58 in the full model; adjusted OR=1.30; 95% CI: 1.05-1.57 in the reduced model). The reduced model showed that only placental abruption (OR=7.24) acted as a confounder. Similar results were found in the full and reduced models including SGA as a potential confounder, while excluding birth weight and gestational age at birth: OR for maternal asthma of 1.17 (95% CI: 0.91-1.59) in the full model and 1.22 (95% CI: 0.98-1.53) in the reduced model. Only SGA (OR=2.21) and placental abruption (OR=7.41 ) have been found to act as confounders in this reduced model.
In table 3 we present the results of the stratified analysis. In the first stratum formed of normal weight (>2500g) and term babies (≥ 37 weeks) there were 11 283 and 25 552 pregnancies in asthmatic and non-asthmatic women, respectively. In this stratum, after adjustment for all potential confounders, asthmatic women were not found to be at increased risk of perinatal mortality (OR=0.97: 95% CI: 0.74-1.29) than non-asthmatic women. In the second stratum formed of babies with a birth weight < 2500 g or born before the 37 th week of gestation there were 1817 and 2490 pregnancies of asthmatic and non-asthmatic women, respectively. In this stratum, asthma was also not found to be associated with an increased risk of perinatal mortality (OR=0.94; 95% CI: 0.73-1.22).
DISCUSSION
In this study we observed a crude significant increased risk of perinatal mortality of 35% among asthmatic women as compared to non-asthmatic women, that did not remain after adjustment for birth weight and gestational age at birth. However, models excluding these variables or adjusted for SGA reveled that asthmatic women tended to be more at risk of perinatal mortality than nonasthmatic women. A stratified analysis showed that among normal weight and term babies, maternal asthma during pregnancy did not increase the risk of perinatal death. Moreover, we found that the proportions of low birth weight and preterm babies were higher among asthmatic than non-asthmatic women and that birth weight and gestational age at birth were very strong predictors of perinatal mortality. These results suggest that birth weight and gestational age at birth are likely to be in the causal pathway between asthma and perinatal mortality.
Twenty previously published studies investigated the association between maternal asthma stillbirth, neonatal mortality and/or perinatal mortality. (2-21) A significant increased risk of neonatal mortality and perinatal mortality among asthmatic women was reported in only two studies (2;13), but 10 of these studies (2;6;9;10;12-16;19) reported only crude estimates. Gordon et al. (13) were the only authors to report a statistically significant increased risk of perinatal mortality among 273 (5.9%) asthmatic women as compared to 30 861 (3.2%) non-asthmatic women (p<0.05) and only Bahna et al. (2) , observed a significantly higher rate of neonatal mortality among 381women with asthma as compared to 112 530 women with no recorded disease before and during pregnancy (p < 0.05). These studies were performed in 1970 and 1972 at a time when neonatal intensive care was probably less sophisticated and foetal surveillance less intensive, explaining the high observed rate of perinatal mortality. Nevertheless, the crude relative risk estimate of perinatal mortality (1.84) is comparable to the crude OR of perinatal mortality (1.35) that we found in our study, both of them being statistically significant.
Ten of these 20 studies (3-5;7;8;11;17;18;20;21) reported estimates that were adjusted or matched for one or several confounding variables such as maternal age, BMI before pregnancy, parity, multiple pregnancy, smoking status, year of delivery, gestational diabetes, pre-existing diabetes, pre-existing hypertension, rupture of membrane and infection of amniotic cavity, and none of them found a significant increased risk of of stillbirth, neonatal mortality or perinatal mortality. The largest of these studies (21) found that the risk of stillbirth was similar in 37 585 pregnancies of asthmatic women compared to 243 434 pregnancies of non-asthmatic women after adjusting for maternal age, smoking status and BMI before pregnancy, year of birth, multiple pregnancy and sex of child (OR=1.04). None of these studies adjusted their results for birth weight or gestational age at birth.
Women with asthma during pregnancy have been found to be more at risk of having babies of low birth weight (2;17) and premature deliveries. (2;17;26) Moreover, asthma exacerbations requiring hospitalization during pregnancy, maternal asthma symptoms and poor asthma control have been associated with an increased risk of low birth weight babies (7), SGA babies (15) and fetal growth restriction. (29) In addition, these adverse perinatal and pregnancy outcomes have been found to increase the risk of perinatal mortality. (27;28;30) Biologic mechanisms could explain the relationship between maternal asthma and low birth weight and preterm babies. Fetal hypoxia (possibly due to poor asthma control) has been suggested as a mechanism for the association between asthma and intra uterine growth restriction. (17) Hypoxic process at the maternal-fetal interface related to maternal asthma was also proposed to lead to placental abruption. (31) Moreover, increased inflammatory cytokines and increased smooth muscle reactivity found in asthmatics may be associated with premature delivery. (9) These data and those of Gordon et al. (13) on the association between severe asthma and perinatal mortality suggest that adequate control of asthma during pregnancy could reduce the risk of having low birth weight and preterm babies, and by consequence might reduce the risk of perinatal deaths in infants of asthmatic women.
Our crude OR showed an increased risk of perinatal mortality among asthmatic women, but our OR adjusted for birth weight and gestational age at birth and the ORs found in the stratified analysis showed no impact of maternal asthma during pregnancy on perinatal mortality. Indeed, in the stratified analysis we found no increased risk of perinatal mortality associated with asthma among normal weight and term babies and among low birth weight or preterm babies. The fact that there was a crude effect of asthma on perinatal mortality, that the effect vanished after adjusting for birth weight and gestational age at birth, that there is a higher prevalence of low birth weight and preterm babies among asthmatic women, that birth weight and gestational age at birth are very strong predictors of perinatal mortality and that there was no effect of asthma among normal weight and term babies suggest that asthma mainly increases the risk of perinatal mortality through lowering the weight of the baby and increasing the risk of a preterm delivery.
This study has several strengths. Using the administrative databases of Quebec presents certain advantages since they provided a large sample size of pregnant asthmatic and non-asthmatic women as well as the possibility of adjusting the risk estimates for a wide variety of potential confounders. Moreover, the information recorded in the administrative databases is prospectively collected, independently of the outcome. In addition, the diagnoses recorded in the RAMQ databases for the identification of patients with asthma are physician-based and have been shown to be valid. (23) However, this study has a few limitations that should be kept in mind when interpreting the results. Some maternal characteristics are not available in the databases, such as cigarette smoking and obesity. Studies have found that maternal smoking is associated with an increased risk of perinatal mortality (32) and asthmatic women might be more likely to smoke than nonasthmatic women. (8;11) Therefore, not adjusting for smoking could result in unadjusted confounding. However, it is expected that a large part of the impact of cigarette smoking would group.bmj.com on April 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from be captured by the variables birth weight, gestational age at birth and placental abruption that are included in our model. Indeed, the increased risk of stillbirth and perinatal mortality among smoking mothers is generally explained by fetal growth restriction, very early delivery and placenta abruption. (32;33) Maternal smoking is associated to fetal hypoxia due to the reduction of the uteroplacental blood flow and the increase in vascular resistance may partly explain the association between smoking and reduced fetal growth and also may contribute to the increased risk of placental abruption. (34) Obesity might act as a confounder in the association between maternal asthma and perinatal mortality since obesity have been found to be more prevalent in asthmatic women compared to non-asthmatic women (35) and that obesity has been associated with an increase in risk of stillbirth. (36) Not adjusting for obesity in our study might have over estimate the impact of asthma on perinatal mortality.
In addition, the RAMQ databases provide medication information only for welfare recipients and residents who are covered by Quebec's Public Prescription Drug Insurance Plan and residents who are covered by a private drug insurance plan are excluded. This led to a sample under represented with women with a high socio-economic status. Socio-economic status has been associated with an increased risk of perinatal mortality. (37) Thus, generalization of our results may be limited to women with lower socio-economic status.
In conclusion, the increased risk of low birth weight baby and premature delivery among asthmatic women may partly explain the association between maternal asthma and the increased risk of perinatal mortality. 
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Articles on similar topics can be found in the following collections Mean pre-and post-challenge values were analysed with a paired t test. Analyses were performed using SPSS version 15.0 (Chicago, Illinois, USA).
The mean age of the patients was 38. 5 years. Thirty-eight patients had a methacholine PC 20 ,8 mg/ml. The mean fall in FEV 1 was 21%. Geometric mean pre-challenge FE NO was 20.4 ppb compared with 16.9 ppb post-challenge, a difference of 17% (95% CI 13% to 21%, p,0.001; fig 1) . Geometric mean CA NO was 2.9 ppb pre-challenge and 1.9 ppb post-challenge, a difference of 31% (95% CI 17% to 43%, p,0.001). Differences in NO at flow rates of 50, 100 and 200 ml were 15% (95% CI 10% to 19%), 11% (95% CI 6% to 16%) and 17% (95% CI 11% to 22%), respectively (p,0.001). Baseline values for FE NO and CA NO showed no correlation with methacholine PC 20 , baseline FEV 1 or final percentage fall in FEV 1 . The percentage change in CA NO following challenge showed a positive correlation with the baseline value (r = 0.59, p,0.001).
To our knowledge, this is the first study to report the effects of methacholine challenge on CA NO . We have shown that methacholine challenge significantly reduces CA NO , and this effect is relatively more marked than for FE NO . The effect on FE NO is known, and is thought to be due to washout of nitric oxide from the airways. There was a proportionally greater suppression of FE NO at 200 ml (17%) than at 50 ml (15%) and 100 ml (11%). This has a more significant effect on the slope of the regression line and hence the CA NO is relatively more suppressed than FE NO . This is an important consideration for planning and interpreting study visits in clinical trials. 
